Thyroid hormone (triiodothyronine [T 3 ]) regulates gene expression by binding to high-affinity nuclear receptors. Thyroid hormone receptors (TRs) recognize specific response element sequences in the promoters of T 3 -target genes and activate or repress transcription in response to hormone. In this paper, we review the TR proteins and thyroid hormone response elements (TREs) to which they bind, the mechanisms of action of TRs bound to the TRE in basal and liganded conformations, and the interacting proteins implicated in these complexes. We then briefly consider the cross-talk with other signaling pathways and introduce the idea that T 3 may also act rapidly via nongenomic actions located on membranes. We discuss patterns of gene expression and specific actions of the various TR isoforms and consider the novel TR isoform specific ligands.
T
HYROID HORMONE RECEPTORS (TRs) are members of the nuclear receptor superfamily and possess the conserved protein domain structure present in all family members. These include a variable N-terminal domain, a DNA binding domain followed by a hinge region, and a C-terminal ligand binding, dimerization, and transactivation domain.
Two genes, THRA (NR1A1) and THRB (NR1A2), encode the TRa and TRb isoforms in most vertebrates. The THRA gene is transcribed as TRa 1 and TRa 2 mRNAs, which differ by alternative splicing of 39 exons, resulting in distinct C terminal domains (Fig. 1 ). TRa 1 binds T 3 and DNA and is a functional receptor, whereas TRa 2 fails to bind hormone and acts as a weak antagonist in vitro. Recently Da 1 and Da 2 isoforms have been identified that are transcribed from a novel promoter in intron 7 (1) ( Table 1) . These shorter variants lack the DNA binding domain and act as dominant negative antagonists (2) .
In mammals, the THRB gene is transcribed as TRb 1 and TRb 2 mRNAs, which are generated by separate promoter usage and alternative splicing in the 59 region resulting in distinct b 1 and b 2 protein N-termini (Fig. 1) . Two further alternatively spliced mRNAs from the rat THRB gene were recently identified and are transcribed from a third TRb promoter (3) . TRb 3 has two novel 59 exons spliced on to the first exon common to both TRb 1 and TRb 2 . This results in translation of a unique 23 amino acid N-terminal region proximal to conserved DNA and triiodothyronine (T 3 ) binding domains. TRb 1 , TRb 2 , and TRb 3 are fully functional receptors. The Db 3 mRNA omits the exon containing the TRb 3 start codon and is translated from the next ATG codon as a truncated protein lacking both the N terminal and DNA binding domains. Preliminary data indicate that Db 3 is a potent repressor in vitro.
Thyroid Hormone Response Elements and Target Genes
TRs bind DNA as heterodimers with the retinoid X receptor (RXR) or possibly as homodimers. They bind to response elements that contain two hexameric half-sites with the consensus sequence G/AGGTC/GA that are arranged in palindromic (P), inverted palindrome (IP), or direct repeat (DR) separated by four nucleotide (DR4) configurations. To date, the majority of natural thyroid hormone response elements (TREs) characterized and the genes they control are positively regulated by T 3 and contain hexamers that may diverge significantly in sequence from the idealized consensus (4). Intriguingly, recent DNA microarray analysis of T 3 -regulated gene expression patterns in mouse liver have suggested that there are more negatively regulated T 3 -target genes (n 5 41) than positive ones (n 5 14) (5). In general, T 3 -stimulated-genes were involved in gluconeogenesis (e.g., glucose-6-phosphatase), glycogenolysis, lipogenesis (e.g., Spot14), cell proliferation (e.g., B61, an Eck receptor tyrosine kinase ligand), and apotosis (e.g., protein kinase C inhibitor) while genes repressed by T 3 included some involved in insulin signal transduction, cell immunity (e.g., FK506-binding proteins), extracellular matrix structure, cell architecture (e.g., various actin isoforms), protein glycosylation (e.g., a-2,3-sialyltransferase), and mitochondrial function (5). However, it is interesting to note that these microarray studies did not identify induction of malic enzyme, a well-described T 3 -target gene containing a well-characterized TRE in its promoter (4) . This suggests that T 3 regulation of gene expression is time dependent and may vary between species and/or mouse strain (5).
Molecular Mechanisms of TR Action

Absence of ligand
Unlike members of the nuclear receptor superfamily that are activated by classic steroid hormones, TRs can heterodimerize with RXR and bind DNA in the absence of ligand. This binding actively represses or silences basal target gene transcription. Yeast two-hybrid screens for interacting proteins using the TR or RXR as bait identified NCoR1 (nuclear receptor co-repressor-1), a ubiquitously expressed 270-kd nuclear protein, and SMRT (silencing mediator for retinoid and thyroid receptors), respectively (reviewed in Hu and Lazar [6] ). Within the interaction domain of the corepressors is a consensus LXXLL amino acid motif. The motifs in both NCoR1 and SMRT interact with helices 3, 5, and 6 of TR, which form part of the ligand-binding pocket in the Cterminal region of the receptor. NCoR1 and SMRT both also interact with bridging protein sin3 and histone deacetylases HDAC1 or 3 as shown in Figure 2 (reviewed in Yen [7] ). In addition, TRs communicate directly with the transcription factor TFIIB and SMRT interacts with TFIIB, TAFII32, and TAFII70 so that the nuclear receptor links both to histone modulating factors and the general transcription machinery.
NCoR1 and SMRT also interact with a wide range of other nuclear receptors (NRs), leading to the possibility of crosstalk between them but further suggesting a surprising lack of specificity in the system. However, two corepressors, Alien and TRUP1, have been identified that only interact with a subset of NRs. Alien interacts with TRs but not with retinoic acid receptor (RAR), RXR, or glucocorticoid receptor (GR); it also interacts with sin3 but not with NCoR or SMRT (8) . TRUP1 interacts with TR and RAR but not with RXR or estrogen receptor (ER), and it interferes with receptor:DNA binding (9) . Although the precise tissue distribution of these corepressors is unknown, these observations suggest a level of complexity that may provide some specificity for the repression of gene expression by NRs.
Presence of hormone
The binding of T 3 ligand to the TR alters its conformation in such a way that the corepressor complex is replaced by a coactivator complex (Fig. 2) . The SRC or p160 family of coactivators consists of SRC1, TIF1/GRIP1/SRC2 and RAC3/ ACTR/pCIP/AIB-1/SRC3 proteins (reviewed in Leo and Chen [10] ). These proteins contain the LXXLL interaction motifs observed in corepressors. The essential role played by SRC1 in TR action is demonstrated by the finding that SRC1 knockout mice exhibit thyroid hormone resistance in peripheral tissues as a major phenotype (11) . However, there is a compensatory increase in expression of TIF2/GRIP1 in SRC1 null mice, suggesting some redundancy among SRC proteins (12) . The coactivator proteins CBP and p300 interact with a variety of transcription factors and cofactors including the SRC proteins (13) . The CBP-associated factor p/CAF interacts with CBP/p300 and with SRC/p160 to modulate receptor function further. All these proteins (p/CAF, p300, and SRC) possess histone acetylase activity (HAT), leading to the hypothesis that the modification of histones around the TRE promotes an open chromatin conformation allowing greater access for the basal transcriptional machinery.
A second group of ligand-dependent interacting factors were identified as thyroid hormone receptor activating proteins (TRAPs) but these proteins have now been shown to be identical to interacting factors with other nuclear receptors, e.g., vitamin D receptor (VDR)-interacting complex (DRIPs) and mouse mediator complex. This suggests that these additional proteins act in a general coactivator complex (reviewed in Ito and Roeder [14] ). The TRAP complex interacts with the TR ligand binding domain using the LXXLL domains in the subunit of 220 kd, TRAP220. TRAP220 knockout mice die at embryonic day 11 and pla- cental insufficiency was observed; however, because TRAP220 (or PBP/PPARBP) binds a wide range of nuclear receptors it is not possible to assign a precise cause (15) . Interestingly, heterozygous mice show growth delay after weaning and pituitary hypothyroidism, suggesting an important, specific role for TRAP220 in thyroid signaling (16) . TRAP100 coimmunoprecipitates with TRAP220 and contains 7 LXXLL motifs. However, it does not interact directly with TR or other NRs, but via TRAP220, suggesting that other sequences apart from the LXXLL motif are necessary for these interactions (17) .
Thus, a multistep model has been suggested in which SRC complexes interact with TR when T 3 binding occurs, but these proteins are subsequently replaced by the TRAP complexes to optimize transactivation (Fig. 2) (14) . Alternatively, this may represent an additional transactivation pathway not requiring prior interaction with the SRC complex.
Both SRC proteins and TRAP complexes interact with a wide range of other NRs, suggesting a lack of specificity in the system as seen for corepressors. However, three coactivators FHL2, NIX1, and PGC1 have been identified that show a tissue specific expression pattern or only interact with a subset of NRs. FHL2 (four and a half LIM-only protein 2) is expressed only in the heart and is a coactivator of the androgen receptor (18) . NIX1 (neuronal interacting factor X-1) is expressed in neuronal cells and binds RAR and TR in a ligand-dependent manner but not RXR (19) . PGC1 (peroxisome proliferation activated receptor gamma coactivator 1) binds PPARg in ligand independent manner; TRb with a ligand induced potentiation of two-to threefold, both RAR and ERa in a ligand-dependent fashion but does not interact with RXRa. PGC1 is expressed predominantly in brown fat, heart, kidney, and brain (20) .
Cross-talk with Other Signaling Pathways
Cross-talk between NRs and second messenger pathways has also been observed. There is synergy between the second messenger adenylate cyclase cyclic adenosine monophosphate (cAMP)-dependent protein kinase (PKA) and RAR, GR, ER, VDR, and PR (progesterone receptor) (21) . T 3 -induced TR action is also potentiated by PKA-dependent phosphorylation in vitro in a manner independent of TRE structure but dependent on the cell line studied (21) . Furthermore, T 3 has been shown to antagonize prolactin signaling during mammary gland development. This signal is mediated by the janus kinase 2 (JAK2)/signal transducer and activator of transcription 5 (STAT5) pathway and recent direct evidence of antagonism of STAT5 by TRb 1 has been shown in an in vitro overexpression system (22) .
Additional rapid-onset nongenomic effects of thyroid hormones may occur at the cell surface. Thyroxine (T 4 ) can inhibit deiodinase type II activity by promoting targeting of the substrate binding subunit to endosomes in astrocytes (23) . The deiodinase II activity at the membrane is reduced by 50% in 10 minutes. Thus, T 4 may have a direct effect on the synthesis, degradation, and recycling of proteins (23) . T 4 has also been shown to activate mitogen-activated protein kinase (MAPK) within 10 minutes via a nongenomic pathway that acts across the cell membrane (24) . The activated MAPK complexes with TRb 1 and phosphorylates it, causing displacement of SMRT (24) . In addition, T 4 can promote phosphorylation and nuclear uptake of STAT1a and STAT3, an effect blocked by inhibitors of protein tyrosine kinase (PTK) and protein kinase C (PKC) (25) . These authors propose that T 4 binds to the cell surface and activates PKC, which in turn activates MAPK kinase (MEK) to promote phosphorylation of MAPK, STAT1a, and STAT3 (25) .
Furthermore, mitochondria also respond directly to T 3 in less than 30 minutes by increasing oxygen consumption and oxidative phosphorylation in a protein synthesis-independent manner (reviewed in Wrutniak-Cabello et al., [26] ). Within the mitochondrial genome there is a putative TRE in the D-loop region and two truncated TRa proteins have been shown to translocate into the organelle-p48 localizes within the mitochondrial matrix and p28 to the inner membrane. The fast stimulation of organelle transcription is induced by p48, which acts as a T 3 -dependent transcription factor of mitochondrial genes (26) . In addition, nuclear-encoded mitochondrial proteins may also be T 3 regulated via conventional genomic pathways (e.g., mitochondrial acyltransferase and Cyp4A10 [5] ).
TR mRNA Expression
TRa 1 and TRb 1 mRNAs are expressed in most tissues. However, their relative abundance varies and this may represent a possible mechanism for tissue-specific responses to T 3 . For example TRa 1 is the major isoform expressed in heart, whereas TRb 1 predominates in liver. In brain, TRa 1 is the major fetal isoform, but at birth there is a marked increase in the expression of TRb 1 , which is maintained during adult life. TRb 2 expression is largely restricted to the anterior pituitary and hypothalamus, where it acts as the major regulator of the hypothalamo-pituitary-thyroid feedback axis and is regulated by T 3 at the level of transcription (27) . The nonfunctional TRa 2 variant mRNA is expressed widely and is the most abundant TR mRNA expressed, although the physiologic significance of this observation is unknown. TRb 3 and Db 3 mRNAs are also expressed widely, but show differences in expression patterns: TRb 3 is present at highest levels in liver, kidney, and lung, whereas Db 3 predominates in spleen and lung. The relative ratio of expression of the two isoforms differ in hypothyroid, thyrotoxic, and euthyroid rats in individual tissues, suggesting that the alternative mRNA splicing is T 3 -regulated and tissue-specific (3). These observations suggest that the ratio of TRb 3 to Db 3 may influence target tissue responsiveness to T 3 . Da 1 and Da 2 are most highly expressed in intestine and lung and an important role for these two variants in development of the intestine has been proposed (2) . It is important to note, when considering these studies, that most investigations of TR isoform concentrations have concentrated on analysis of mRNA expression, which may correlate poorly with levels of TR protein. For example, as indicated above, TRb 2 mRNA is restricted to pituitary and hypothalamus but TRb 2 protein has been shown to be widely expressed (28) .
TR-Isoform-Specific Functions
Numerous studies have previously examined specific target genes in vitro for TR-isoform-specific responses, however, these are difficult to evaluate in physiological terms. Most recently, new information has been gained in vivo from studies of mice lacking expression of one or more TRs (Table 1 ). Mice lacking the TRa 1 transcript have low heart rate and body temperature and reduced energy expenditure, suggesting a specific role for TRa 1 in cardiac pacemaking and ventricular repolarization. This is supported by the protein expression data which indicates that TRa 1 is the predominant isoform in heart (29) and the data from the TRb agonist, GC-1, that spares the heart (discussed below). Knockout mice lacking TRa 1 and TRa 2 are grossly hypothyroid, growth retarded, and die at weaning of intestinal developmental abnormalities. In contrast, mice that lack all products of the Thra gene are euthyroid with only a mildly increased pituitary sensitivity to thyroid hormones and display a near normal intestinal phenotype with less marked growth retardation. These results imply that the Da 1 and Da 2 isoforms have a major role in intestinal development and suggest a key role for TRa during skeletal development.
Knockout mice lacking all the Thrb isoforms display features similar to human resistance to thyroid hormone syndrome including goiter, peripheral and central resistance to T 3 and deafness. Deletion of only the TRb 2 isoform generates mice with no m-cone photoreceptors in the retina and implicates the TRb 2 isoform as the key mediator of hypothalamo-pituitary-thyroid feedback regulation. TRb 2 null mice also possess intact hearing, indicating that TRb 1 is essential for auditory function (30) .
Nevertheless, the TR knockout mice data also demonstrate significant redundancy between receptor isoforms and the fact that TRa 0/0 b 2/2 mice are viable indicates that TRs are not essential for life per se (31) .
Isoform-Specific Ligands
The potential for thyroid hormones to alter weight and cholesterol clearance has made them a target of pharmaceutical interest. However, the deleterious side effect of tachycardia has resulted in a requirement for TR-isoform-specific ligands that do not affect the heart. The studies of transgenic and knockout mice show that TRa 1 is of major importance in the heart and so efforts have concentrated on TRb-specific ligands that do not activate TRa. Baxter et al. (32) have reviewed selective modifiers of TR action including GC-1 (3,5,39-triiodithyro-oxoacetate), a novel T 3 analogue specifically designed to bind the ligand binding pocket of TRb not TRa. Hypothyroid mice treated with GC-1 had plasma cholesterol decreased to euthyroid levels but did not have the increased heart rate, increased body and heart weights or elevated HCN2 (cardiac pacemaker I f channel) mRNA of mice treated with T 3 . In hypercholesteremic rats, GC-1 had a higher potency to influence cholesterol and thyrotropin than heart rate, confirming the selectivity observed in hypothyroid mice (32) .
Conclusions
The work reviewed here considers strong foundations that have led to a molecular understanding of the mechanism of thyroid hormone action with increasing detail being accumulated in recent years. New genetic models and development of TR-isoform-specific ligands sets the scene for an exciting future in research into T 3 action. This will include a better understanding of detailed effects of individual TRs in specific target organ function and new opportunities to manipulate T 3 signaling in a targeted and therapeutically beneficial fashion. In this context, the heart and cardiovascular system are clear examples of systems where there are major clinical therapeutic possibilities in the near future.
